NEW YORK, Sept. 22, 2016 /PRNewswire/ --
Use this report to:
- Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole
- Identify important trends and provide sales forecasts by product categories and major country markets through 2021
- Study epidemiological data, projections and information on R&D trends, and market potential on a country-by-country basis
- Evaluate the devices and instruments used for the diagnosis and monitoring of diabetes
- The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
- The oral hypoglycemic drugs market should reach $88 billion by 2021 from $67 billion in 2016 at a CAGR of 5.6%, from 2016 to 2021.
- The monitoring devices and accessories market should reach $17 billion by 2021 from $11 billion in 2016 at a CAGR of 9.1%, from 2016 to 2021.
Introduction & Scope
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes, as well as the devices and instruments used for diagnosis and monitoring of diabetes. Special emphasis is given to the major forces contributing to the vigorous growth of the diabetes market. The report identified important trends and provides sales forecasts by product categories and major country markets through 2021; these are based on epidemiological data and projections, plus information on R&D trends and market potential on a country-by-country basis. Healthcare policies, demographics and the wider economic environment are also taken into account.
REASONS FOR DOING THE STUDY
It is widely recognized that the prevalence of the most common type of diabetes mellitus, type 2, is now reaching epidemic proportions all over the world. Cases of type 1 diabetes mellitus are also on the increase, although to a lesser degree. These trends are of great concern, not only to the individuals concerned, but also to governments and providers of healthcare, because the economic consequences of diabetes are vast. They involve not only the direct burden of managing the disease but also its common and often catastrophic complications, including cardiovascular disease, peripheral neuropathy and blindness. Prompt diagnosis and effective treatment of diabetes are not optional but essential priorities for governments and healthcare agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence significance to the suppliers of the drugs used in treatment of the disease and the devices needed for monitoring. The information needs of companies in this field include accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country. A comprehensive refresher section on diabetes is provided as an appendix.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2016-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices such as blood glucose monitors and accessories, and software aids to self-management of the disease by diabetics.
Primary research includes interviews with leading individuals in relevant companies and medical associations, and primary sources of published data, including epidemiological and economic studies, company annual reports, SEC filings and government publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC Research.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. It is also aimed at managers and executives in marketing, research, planning and sales departments who need comprehensive and up-to-date background on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Corporate annual reports and SEC filings, journal articles and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
Read the full report: http://www.reportlinker.com/p04162565-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-markets-for-diabetes-therapeutics-and-diagnostics-300332974.html